Evaluation of Toxoplasma and Toxocara Prevalence in Chronic Kidney Disease (CKD) Patients Using Serologic and Molecular Technique in Selected Medical Centers of Tehran, Iran
,
Abstract
Background: Toxoplasmosis and toxocariasis are two zoonotic diseases with global impact. Chronic kidney disease (CKD) can lead to complications, associated with reduced immune responses that predispose them to frequent parasitic infections. We aimed to determine the prevalence of toxoplasmosis and toxocariasis in CKD patients to propose a new way to control them in dialyses duration in Tehran, Iran.
Methods: Three hundred and sixty-five CKD patients and 72 healthy individuals were tested for anti-Toxoplasma gondii (IgG, IgM) and anti-Toxocara (IgG) antibodies using conventional ELISA technique. IgM positive samples underwent genetic analysis.
Results: Of the 437 samples studied (365 patients and 72 controls), 182 CKD patients (49.8%) and 20 controls (27.9%) were positive for Toxoplasma IgG, and 8 (2.2%) CKD samples were positive for Toxoplasma IgM, while none of the control samples were positive for Toxoplasma IgM. Molecular analysis of the 8 IgM positive samples with B1gene confirmed the presence of Toxoplasma antigen in all of them. Toxocara IgG antibodies showed a lower prevalence in CKD patients (5.7%) compared to controls (9.7%). The study revealed significant differences (P <0.05) in Toxoplasma IgG and IgM antibodies, as well as variables such as dialysis and dialysis duration between the two groups of patients and the control group. However, variables such as Toxocara IgG, age, gender, lupus, and pets showed no significant difference between the control group and the patients.
Conclusion: The collected data in this study could serve as a reference for future studies and may be useful for examination and evaluation of acute and chronic toxoplasmosis before and after starting dialysis.
2. Skariah S, McIntyre MK, Mordue DG. Toxoplasma gondii: determinants of tachyzoite to bradyzoite conversion. Parasitol Res. 2010;107(2):253-60.
3. Dubey JP, Lindsay DS, Speer CA. Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. Clin Microbiol Rev. 1998;11(2):267-99.
4. Lima TS, Lodoen MB. Mechanisms of Human Innate Immune Evasion by Toxoplasma gondii. Front Cell Infect Microbiol. 2019;9:103.
5. Saki J, Mowla K, Arjmand R, Kazemi F, Fallahizadeh S. Prevalence of Toxoplasma gondii and Toxocara canis Among Myositis Patients in the Southwest of Iran. Infect Disord Drug Targets. 2021;21(1):43-8.
6. jenJenkins EJ. Toxocara spp. in dogs and cats in Canada. Adv Parasitol. 2020;109:641-53.
7. Wu T, Bowman DD. Visceral larval migrans of Toxocara canis and Toxocara cati in non-canid and non-felid hosts. Adv Parasitol. 2020;109:63-88.
8. Pawlowski Z. Toxocariasis in humans: clinical expression and treatment dilemma. J Helminthol. 2001;75(4):299-305.
9. Strube C, Heuer L, Janecek E. Toxocara spp. infections in paratenic hosts. Vet Parasitol. 2013;193(4):375-89.
10. Saki J, Eskandari E, Feghhi M. Study of toxoplasmosis and toxocariasis in patients suffering from ophthalmic disorders using serological and molecular methods. Int Ophthalmol. 2020;40(9):2151-2157.
11. Venuthurupalli SK, Hoy WE, Healy HG, Cameron A, Fassett RG. CKD Screening and Surveillance in Australia: Past, Present, and Future. Kidney Int Rep. 2017;3(1):36-46.
12. Inker LA, Titan S. Measurement and Estimation of GFR for Use in Clinical Practice: Core Curriculum 2021. Am J Kidney Dis. 2021;78(5):736-49.
13. Pasala S, Carmody JB. How to use serum creatinine, cystatin C and GFR. Arch Dis Child Educ Pract Ed. 2017;102(1):37-43.
14. Jha V, Prasad N. CKD and Infectious Diseases in Asia Pacific: Challenges and Opportunities. Am J Kidney Dis. 2016;68(1):148-60.
15. Casarosa L, Papini R, Mancianti F, Abramo F, Poli A. Renal involvement in mice experimentally infected with Toxocara canis embryonated eggs. Vet Parasitol. 1992;42(3-4):265-72.
16. Huwer M, Sanft S, Ahmed JS. Enhancement of neutrophil adherence to Toxocara canis larvae by the C3 component of complement and IgG antibodies. Zentralbl Bakteriol Mikrobiol Hyg A. 1989;270(3):418-23.
17. Levy M, Bourrat E, Baudouin V, Guillem C, Peuchmaur M, Deschenes G, et al. Toxocara canis infection: Unusual trigger of systemic lupus erythematosus. Pediatr Int. 2015;57(4):785-8.
18. Mousavi M, Saravani R, Jafari Modrek M, Shahrakipour M, Sekandarpour S. Detection of Toxoplasma gondii in Diabetic Patients Using the Nested PCR Assay via RE and B1 Genes. Jundishapur J Microbiol. 2016;9(2):e29493.
19. Arab-Mazar Z, Fallahi S, Yadegarynia D, et al. Immunodiagnosis and molecular validation of Toxoplasma gondii infection among patients with end-stage renal disease undergoing haemodialysis. Parasitology. 2019;146(13):1683-9.
20. Overgaauw PA, van Knapen F. Veterinary and public health aspects of Toxocara spp. Vet Parasitol. 2013;193(4):398-403.
21. Adamczak M, Surma S. Metabolic Acidosis in Patients with CKD: Epidemiology, Pathogenesis, and Treatment. Kidney Dis (Basel). 2021;7(6):452-67.
22. Bao X, Borne Y, Muhammad IF, et al. Complement C3 and incident hospitalization due to chronic kidney disease: a population-based cohort study. BMC Nephrol. 2019;20(1):61.
23. Saki J, Khademvatan S, Soltani S, Shahbazian H. Detection of toxoplasmosis in patients with end-stage renal disease by enzyme-linked immunosorbent assay and polymerase chain reaction methods. Parasitol Res. 2013;112(1):163-8.
24. Romagnani P, Remuzzi G, Glassock R, et al. Chronic kidney disease. Nat Rev Dis Primers. 2017;3:17088.
25. Rasti S, Hassanzadeh M, Soliemani A, et al. Serological and molecular survey of toxoplasmosis in renal transplant recipients and hemodialysis patients in Kashan and Qom regions, central Iran. Ren Fail. 2016;38(6):970-3.
26. Saadat F, Mahmoudi MR, Rajabi E, et al. Seroepidemiology and Associated Risk Factors of Toxoplamsa gondii in Hemodialysis Patients. Acta Parasitol. 2020;65(4):906-12.
27. Tong DS, Yang J, Xu GX, Shen GQ. [Serological investigation on Toxoplamsa gondii infection in dialysis patients with renal insufficiency]. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2011; 23(2):144, 153.
28. Zotos PG, Psimenou E, Roussou M, Kontogiannis S, Panoutsopoulos A, Dimopoulos AM. Nephrotic syndrome as a manifestation of Toxocara canis infection. Nephrol Dial Transplant. 2006;21(9):2675-6.
29. Macejova Z, Kristian P, Janicko M, et al. The Roma Population Living in Segregated Settlements in Eastern Slovakia Has a Higher Prevalence of Metabolic Syndrome, Kidney Disease, Viral Hepatitis B and E, and Some Parasitic Diseases Compared to the Majority Population. Int J Environ Res Public Health. 2020;17(9): 3112.
| Files | ||
| Issue | Vol 20 No 2 (2025) | |
| Section | Original Article(s) | |
| Keywords | ||
| Chronic kidney diseases Toxoplasma Toxocara | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
